Looking for a Top Momentum Pick? Why NuVasive, Inc. (NASDAQ:NUVA) is a Great Choice

NuVasive, Inc. (NASDAQ:NUVA) price on Thursday, Dec 24, dropped -0.16% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $53.62.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

A look at the stock’s price movement, the close during the last trading session was $53.71, moving within a range at $53.01 and $54.14. The beta value (5-Year monthly) is 1.32 while the PE ratio in trailing twelve months stood at 0. Turning to its 52-week performance, $81.91 and $28.55 were the 52-week high and 52-week low respectively. Overall, NUVA moved 11.64% over the past month.

NuVasive, Inc.’s market cap currently stands at around $2.61 Billion, with investors looking forward to this quarter’s earnings report slated for Feb 18, 2021- Feb 22, 2021. The company has a Forward Dividend ratio of 0, with its dividend yield at 0%. As such, investors might be keen on a downside in the stock’s price ahead of the scheduled earnings report. Analysts project the company’s earnings per share (EPS) to be $0.59, which has seen fiscal year 2020 EPS growth forecast to decrease to $1.24 and about $2.4 for fiscal year 2021. Per the data, EPS growth is expected to be -0.5% for 2020 and 0.94% for the next financial year.

Analysts have a consensus estimate of $305.95 Million for the company’s revenue for the quarter, with a low and high estimate of $283.87 Million and $316.67 Million respectively. The average forecast suggests up to a -1.4% decline in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2020 to shrink to $1.07 Billion, representing a -8.8% drop on that reported in the 2019 financial year.

Turning to the stock’s technical picture we see that short term indicators suggest on average that NUVA is a Hold. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.

19 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 8 analyst(s) rate the stock as a Hold, 8 recommend NUVA as a Buy and none give it an Outperform rating. Meanwhile, 1 analyst(s) rate the stock as Underperform and 2 say it is a Sell. As such, the average rating for the stock is Overweight which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.

The technical evaluation for the stock shows the PEG ratio is 0, with NUVA’s current price about 11.81% and 11.37% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 68.1, while 7-day volatility ratio is 3.99% and 3.48% in the 30-day chart. Further, NuVasive, Inc. (NUVA) has a beta value of 1.32, and an average true range (ATR) of 1.86. Analysts have given the company’s stock an average 52-week price target of $61.06, forecast between a low of $48 and high of $76. Looking at the price targets, the low is -10.48% off current price level while to achieve the yearly target high price needs to move +41.74%. Nonetheless, investors will most likely welcome a +11.9% jump to $60 that is the analysts’ median price.

In the market, a comparison of NuVasive, Inc. (NUVA) and its peers suggest the former has performed considerably weaker. Data shows NUVA’s intraday price has changed -0.16% today and -30.33% over the past year. Comparatively, Abbott Laboratories (ABT) has moved +0.84% on the day and only +24.14% in the past 12 months. Looking at another peer, we see that Medtronic Inc (MDT) price has surged 0.08% on the day. However, the stock is 1.29% off its price today a year ago. Moreover, Stryker Corp (SYK) is also down -0.16% in today trading while keeping a downtrend of -30.33% over the past year. If we look at the PE ratio, we find that NuVasive, Inc.’s ratio stands at 0 compared to Abbott Laboratories’s 57.63 and Medtronic Inc’s 43.96. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are up 0.35% and 0.23% respectively on the day as seen in early trades.

If we refocus on NuVasive, Inc. (NASDAQ:NUVA), historical trading data shows that trading volumes averaged 1.09 Million over the past 10 days and 861.49 Million over the past 3 months. The company’s latest data on shares outstanding shows there are 51.28 Million shares.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

As per Thomson Reuters, 0.71% of NuVasive, Inc.’s shares are in the hands of company insiders while institutional holders own 109.5% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.04 Million on November 29, 2020, giving us a short ratio of 3.89. The data shows that as of November 29, 2020 short interest in NuVasive, Inc. (NUVA) stood at 7.87% of shares outstanding, with shares short dropping from 5.98 Million registered in October. Current price change has pushed the stock -30.67% YTD, which shows the risk of further decline is there. It is this reason that could see investor optimism for the NUVA stock might rise going into the next quarter.

A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on..

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.


Latest posts